PVR and acute myeloid leukemia: These findings collectively suggest that Hu-B03 CAR-T cells maintained strong antitumor efficacy against CD155+ AML and NSCLC in vitro and in vivo while potentially reducing immunogenicity, thereby enhancing their suitability for clinical applications.